KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $566.8 million.

  • Royalty Pharma's Shares Outstanding (Diluted Average) fell 485.64% to $566.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $566.8 million, marking a year-over-year decrease of 485.64%. This contributed to the annual value of $594.1 million for FY2024, which is 145.83% down from last year.
  • Royalty Pharma's Shares Outstanding (Diluted Average) amounted to $566.8 million in Q3 2025, which was down 485.64% from $570.2 million recorded in Q2 2025.
  • Royalty Pharma's Shares Outstanding (Diluted Average)'s 5-year high stood at $607.3 million during Q1 2023, with a 5-year trough of $414.8 million in Q4 2021.
  • Over the past 5 years, Royalty Pharma's median Shares Outstanding (Diluted Average) value was $602.9 million (recorded in 2023), while the average stood at $579.8 million.
  • In the last 5 years, Royalty Pharma's Shares Outstanding (Diluted Average) soared by 7152.47% in 2021 and then tumbled by 485.64% in 2025.
  • Over the past 5 years, Royalty Pharma's Shares Outstanding (Diluted Average) (Quarter) stood at $414.8 million in 2021, then grew by 5.59% to $438.0 million in 2022, then soared by 37.66% to $602.9 million in 2023, then decreased by 1.46% to $594.1 million in 2024, then decreased by 4.6% to $566.8 million in 2025.
  • Its last three reported values are $566.8 million in Q3 2025, $570.2 million for Q2 2025, and $578.1 million during Q1 2025.